Phase 2 Head and Neck Cancer Trial, Recruiting NCT07407582 Sponsor: University of Arizona Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT07407582
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be willing and able to give your consent to participate before any study activities begin.
  • You must be at least 18 years old (male or female) at the time you sign the consent form.
  • You must be generally healthy and able to carry out normal daily activities, with little or no limitation from your illness (confirm with trial site).
  • Your cancer must have been confirmed through a tissue or cell sample, and you must not have received any treatment for it yet.
  • You must be scheduled to receive a standard, FDA-approved chemotherapy treatment that includes cisplatin (a specific chemotherapy drug) at a total dose of at least 200 mg/m², for any solid tumour cancer that has not yet been treated.

Who may not be able to join:

  • You have previously been treated with cisplatin for cancer.
  • You are currently taking other medications that can damage hearing, and these cannot be safely stopped or swapped for a safer alternative.
  • You are planned to have radiation therapy to the head or neck before, during, or within 3 months after finishing cisplatin treatment.
  • You have had a serious allergic reaction to sulfite, sodium thiosulfate, or related ingredients in the past.
  • Your blood sodium level is too high, or you have a significant imbalance in certain minerals in your blood (confirm with trial site).
  • Your cisplatin treatment is planned to be given over more than 6 hours per infusion.
  • You are pregnant, breastfeeding, or could become pregnant and are unwilling to use contraception during the treatment period.
  • You are a male whose partner is pregnant, and you are unwilling to abstain from sex or use a condom during treatment.
  • You are unlikely to be able to attend all required study visits or complete all study-related tasks.
  • You have another significant health condition that, in your doctor's opinion, could put you at risk or interfere with the study (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lisa Davis, PharmD, University of Arizona

Phone: 520-694-2873

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of Arizona
Registry
ClinicalTrials.gov
Start date
18 May 2026
Est. completion
30 April 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Efficacy of intravenous STS to reduce hearing impairment associated with cisplatin

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov